Vertex Pharmaceuticals (Canada) Inc.
Registration:
7
of
7
(2024-07-19
to
present)
Details Regarding the Identified Subject Matter
Subject matters
|
Details
|
Categories
|
Health
|
Engagement with officials on Bill S-280, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
|
Legislative Proposal, Bill or Resolution
|
Health
|
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
|
Policies or Program
|
Budget, Health
|
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.
|
Policies or Program
|
Health
|
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
|
Regulation, Policies or Program
|
Health, Industry
|
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
|
Policies or Program
|
Health
|
Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
|
Policies or Program
|
Health
|
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada review processes to implement an orphan drug regulatory framework.
|
Regulation, Policies or Program
|
Health
|
The development of a national pharmacare program, including the Canada Drug Agency, a national formulary and a rare diseases strategy
|
Policies or Program
|